Moreover, it does not show the impairment of TP53 and MYC signaling pathway typically observed in DLBCL or HGBCL with MYC and BCL2 rearrangements, whereas it exhibits impairment of E2F targets [148]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.